In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Antaxone; Celupan; Contrave (Takeda); Depade (Mallinckrodt); Nalorex (Bristol-Myers Squibb); Nemexin; Opizone (Genus); ReVia (Meda); Trexan; Troxyca (Pfizer); Vivitrex (Alkermes); Vivitrol (Alkermes)
- INDICATIONS: Substance abuse, opioid dependence, alcohol dependence
- CLASS: Anti-obesity / weight loss pharmacotherapy, Opioid antagonist
- HALF-LIFE: 4 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bremelanotide, Lofexidine, Opioid analgesics, Opioid containing medications
- See adverse reactions attributed to class:
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses.
Troxyca is naltrexone and oxycodone.
Contra-indicated in acute hepatitis or liver failure; patients receiving opioid analgesics, with current physiologic opioid dependence, or in acute opioid withdrawal.
Contrave, a combination of naltrexone and bupropion, has been approved by the FDA for chronic weight management.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of naltrexone/bupropion in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/19/2025
